Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Description

BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.

Conditions

Bladder Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.

Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Condition
Bladder Cancer
Intervention / Treatment

-

Contacts and Locations

Little Rock

Arkansas Urology Research Center, Little Rock, Arkansas, United States, 72211

Indianapolis

Indiana University School of Medicine, Indianapolis, Indiana, United States, 46202

Saint Louis

Washington University, Saint Louis, Missouri, United States, 63130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients 18 Years and older
  • * Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy.
  • * Patients who are able to provide legally effective informed consent.
  • * Patients who are able to provide minimum 30mL of voided urine.
  • * Patients planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Early is Good Inc.,

Study Record Dates

2025-12-31